Furthermore, there is a significant reduction in the overall survival in CRC patients with a mutated BRAF/MEK/PI3K oncogenic signature (Figure 6F), underlining its role in tumor aggressiveness and resistance to therapy. The gene discussed is BRAF; the disease is neoplasm.